American Journal of Cardiology
Volume 102, Issue 5 , Pages 535-540 , 1 September 2008

Impact of Optimal Medical Therapy and Revascularization on Outcome of Patients With Chronic Kidney Disease and on Dialysis Who Presented With Acute Coronary Syndrome

Received 11 March 2008 ,Revised 23 April 2008 ,Accepted 23 April 2008.

References 

  1. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–1295
  2. McCullough PA. Why is chronic kidney disease the “spoiler” for cardiovascular outcomes?. J Am Coll Cardiol. 2003;41:725–728
  3. Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, Solomon DH, Avorn J. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol. 2006;1:796–801
  4. Charytan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J. 2006;152:558–564
  5. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201–208
  6. Schiele F, Legalery P, Didier K, Meneveau N, Seronde MF, Caulfield F, et al. Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. Am Heart J. 2006;151:661–667
  7. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol. 2003;92:509–514
  8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  9. Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation. 2007;116:1465–1472
  10. Johnston N, Jernberg T, Lagerqvist B, Wallentin L. Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease. Am Heart J. 2006;152:1052–1058
  11. Yasuda K, Kasuga H, Aoyama T, Takahashi H, Toriyama T, Kawade Y, et al Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 2006;17:2322–2332
  12. Tricoci P, Lokhnygina Y, Berdan LG, Steinhubl SR, Gulba DC, White HD, et al Time to coronary angiography and outcomes in patients with high-risk non–ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007;116:2669–2677
  13. Herzog CA, Ma Stigant C, Izadnegahdar M, Levin A, Buller CE, Humphries KH. Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era. Am J Kidney Dis. 2005;45:1002–1009
  14. Hassani SE, Chu WW, Wolfram RM, Kuchulakanti PK, Xue Z, Gevorkian N, et al. Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. J Invasive Cardiol. 2006;18:273–277
  15. Halkin A, Selzer F, Marroquin O, Laskey W, Detre K, Cohen H. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. Invasive Cardiol. 2006;18:577–583
  16. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92
  17. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607–617
  18. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996;94:2743–2748
  19. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138–141
  20. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61
  21. Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 2004;24:1246–1252
  22. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999–1007
  23. Bonello L, Basire A, Sabatier F, Paganelli F, Dignat-George F. Endothelial injury induced by coronary angioplasty triggers mobilization of endothelial progenitor cells in patients with stable coronary artery disease. Thromb Haemost. 2006;4:979–981
  24. Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality in incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol. 2003;14:415–424
  25. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int. 2005;67:1500–1508
  26. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, et al Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;19:1291–1299
  27. Dimeny EM. Cardiovascular disease after renal transplantation. Kidney Int. 2002;61:s78–s84
  28. Lahoz C, Mostaza JM, Mantilla MT, Taboada M, Tranche S, López-Rodriguez I, et al. Achievement of therapeutic goals and utilization of evidence-based cardiovascular therapies in coronary heart disease patients with chronic kidney disease. Am J Cardiol. 2008;101:1098–1102
  29. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047

 Dr. Bonello is supported by a grant from the Association pour le Développement des Recherches Biologiques et Médicales au Centre Hospitalier Régional de Marseille, France.

PII: S0002-9149(08)00755-8

doi: 10.1016/j.amjcard.2008.04.040

American Journal of Cardiology
Volume 102, Issue 5 , Pages 535-540 , 1 September 2008

Article Tools

* Image Usage & Resolution